Investigated for use/treatment in diabetes mellitus type 2.
- Mechanism
- Curator reviewed
AMG-222 is an orally active, small molecule inhibitor of Dipeptidyl Peptidase IV (DPP-IV). DPP-IV inactivates glucagon-like peptide-1 (GLP-1), an important mediator of blood glucose levels following meals. DPP-IV inhibitors have been clinically shown to provide long term improvement of glucose control without the risk of hypoglycemia, and to improve the function of pancreatic beta cells, the cells responsible for the production of insulin. DPP-IV inhibitors represent a novel approach to the treatment of type II diabetes.
- Primary indication
- Investigated for use/treatment in diabetes mellitus type 2.Curator reviewed
- Formula / weight
- C32H39N9O3 · 597.724 g/mol (avg)
- Code names
- ALS 2-0426 · AMG-222
Resolves to
NVSWJKWHLUTHLP-CPJSRVTESA-NSMILES[H][C@](C)(CC1(C2=NNN=N2)C2=CC=C(C=C2CCC2=CC(=CC=C12)C(=O)N(C)C)C(=O)N(C)C)NCC(=O)N1CCC[C@@]1([H])C#NWhat you can answer from here — as of March 06, 2025
Which drugs share a target with AMG-222, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account